Jason Zemansky
Stock Analyst at Bank of America Securities
(4.80)
# 517
Out of 4,634 analysts
442
Total ratings
58.6%
Success rate
20.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintained: Buy | $209 → $214 | $131.10 | +63.23% | 51 | Aug 7, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | n/a | $293.15 | - | 10 | Aug 7, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $86 | $63.81 | +34.78% | 3 | Aug 6, 2026 | |
| CYTK Cytokinetics | Reiterated: Hold | $83 → $85 | $76.76 | +10.73% | 48 | Aug 6, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $64 → $71 | $61.32 | +15.79% | 30 | Aug 5, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $29 → $26 | $20.40 | +27.45% | 35 | Aug 5, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Buy | $10 | $3.61 | +177.01% | 19 | Aug 3, 2026 | |
| RCUS Arcus Biosciences | Reiterated: Hold | $25 → $29 | $28.62 | +1.33% | 37 | Aug 3, 2026 | |
| MDGL Madrigal Pharmaceuticals | Reiterated: Hold | $553 → $543 | $510.04 | +6.46% | 27 | Jul 30, 2026 | |
| BIIB Biogen | Reiterated: Hold | $215 → $219 | $207.94 | +5.32% | 15 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $9.57 | +213.48% | 40 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.47 | +142.91% | 5 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $101 | $84.48 | +19.55% | 36 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.44 | +227.87% | 13 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 → $42 | $26.51 | +58.43% | 15 | Jun 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $11.15 | +79.37% | 16 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 | $14.71 | -18.42% | 11 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 → $32 | $9.29 | +244.46% | 3 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.3971 | +1,662.78% | 19 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $15 → $12 | $4.14 | n/a | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $1 | $4.07 | n/a | 3 | Dec 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.60 | n/a | 2 | Nov 17, 2023 |
Insmed
Aug 7, 2026
Maintained: Buy
Price Target: $209 → $214
Current: $131.10
Upside: +63.23%
Ligand Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $293.15
Upside: -
BioMarin Pharmaceutical
Aug 6, 2026
Reiterated: Buy
Price Target: $86
Current: $63.81
Upside: +34.78%
Cytokinetics
Aug 6, 2026
Reiterated: Hold
Price Target: $83 → $85
Current: $76.76
Upside: +10.73%
Travere Therapeutics
Aug 5, 2026
Maintained: Buy
Price Target: $64 → $71
Current: $61.32
Upside: +15.79%
Syndax Pharmaceuticals
Aug 5, 2026
Maintained: Buy
Price Target: $29 → $26
Current: $20.40
Upside: +27.45%
Rocket Pharmaceuticals
Aug 3, 2026
Maintained: Buy
Price Target: $10
Current: $3.61
Upside: +177.01%
Arcus Biosciences
Aug 3, 2026
Reiterated: Hold
Price Target: $25 → $29
Current: $28.62
Upside: +1.33%
Madrigal Pharmaceuticals
Jul 30, 2026
Reiterated: Hold
Price Target: $553 → $543
Current: $510.04
Upside: +6.46%
Biogen
Jul 29, 2026
Reiterated: Hold
Price Target: $215 → $219
Current: $207.94
Upside: +5.32%
Jul 27, 2026
Maintained: Buy
Price Target: $30
Current: $9.57
Upside: +213.48%
Jul 27, 2026
Maintained: Buy
Price Target: $6
Current: $2.47
Upside: +142.91%
Jul 22, 2026
Maintained: Buy
Price Target: $101
Current: $84.48
Upside: +19.55%
Jun 11, 2026
Maintained: Buy
Price Target: $8
Current: $2.44
Upside: +227.87%
Jun 10, 2026
Reiterated: Buy
Price Target: $37 → $42
Current: $26.51
Upside: +58.43%
Jun 3, 2026
Reiterated: Hold
Price Target: $20
Current: $11.15
Upside: +79.37%
Jun 3, 2026
Reiterated: Sell
Price Target: $12
Current: $14.71
Upside: -18.42%
Jun 3, 2026
Reiterated: Buy
Price Target: $34 → $32
Current: $9.29
Upside: +244.46%
Feb 17, 2026
Reiterated: Buy
Price Target: $7
Current: $0.3971
Upside: +1,662.78%
Mar 28, 2024
Reiterated: Sell
Price Target: $15 → $12
Current: $4.14
Upside: n/a
Dec 26, 2023
Maintained: Sell
Price Target: $1
Current: $4.07
Upside: n/a
Nov 17, 2023
Rated: Hold
Price Target: n/a
Current: $15.60
Upside: n/a